P

Parabilis Medicines

Develops first-in-class cancer therapeutics

Associate Director - Structural Biology

Biology & BiotechPosted on Nov 12
Full-timeCambridge, MA, USA

About the Job

Requirements

  • A PhD in Structural Biology, Biophysics, Biochemistry, Chemistry, or a related field, with 8 or more years of industry experience and increasing responsibility in a drug discovery setting.
  • Deep, hands-on expertise in X-ray crystallography or single-particle cryo-electron microscopy, from sample preparation through structure determination and refinement, with working knowledge of the other technique and a willingness to build proficiency.
  • A hands-on leadership mindset and a genuine commitment to working side by side with the team.
  • Proven impact in biotech or pharmaceutical drug discovery, with structures that informed design decisions, including challenging targets such as protein–protein interactions, degrader ternary complexes, flexible or transient assemblies, or peptide-bound systems.
  • A track record managing external structural biology capacity, including contract research organization selection, scoping, and day-to-day management to agreed timelines and quality standards.
  • Practical understanding of complementary methods, including nuclear magnetic resonance, small-angle X-ray scattering, hydrogen-deuterium exchange mass spectrometry, and biophysical approaches, and judgment about when each is the fastest route to an answer.
  • Fluency with computational colleagues, including understanding how structural data is used in modeling, docking, and free energy calculations, and how experimental restraints can be used as modeling input.
  • Ability to use artificial intelligence tools for day-to-day work; baseline proficiency is expected.
  • Ability to work on-site and attend in-person meetings.

Responsibilities

  • Partner with the Head of Computational Drug Discovery to shape structural biology capability, external partnerships, and method selection; translate structural insight into design hypotheses and program recommendations for cross-functional teams and senior leadership; and provide input on investments in external capacity, instrumentation, and software.
  • Drive rapid, parallel structure determination of Helicon-mediated complexes, using crystallography for high-resolution detail of the protein of interest and binary protein–Helicon complexes and cryo-electron microscopy for full ternary assemblies when crystallization is unlikely; pursue both approaches concurrently where appropriate and add complementary methods when they answer program questions faster than full structure determination.
  • Improve workflows and turnaround times by identifying bottlenecks, building and automating in-house sample-to-screen workflows, and evaluating automation, software, and artificial intelligence-enabled tools to deliver reliable, high-quality structural information.
  • Manage external contract research organization capacity to deliver on program timelines, including partner selection, scoping, throughput, and quality and turnaround expectations.
  • Lead and develop the team by working alongside team members, mentoring internal scientists, directing contractors, setting technical standards, giving constructive feedback, and supporting scientific growth.
  • Partner with computational drug discovery on restraint-guided modeling and structural data infrastructure, using lower-resolution experimental data as quantitative restraints to constrain and validate ternary-complex models and helping establish a versioned, programmatically accessible structure repository.

Desired Qualifications

  • Experience managing direct reports is preferred.
  • Experience with protein production and construct engineering for difficult complexes, automation of crystallization or grid screening, scripting such as Python, or structure-based design of degraders is a plus.
  • Advanced or innovative use of artificial intelligence tools is a strong plus.

About the Company

Parabilis Medicines

Develops first-in-class cancer therapeutics

Parabilis Medicines advances drug discovery for cancer by developing a novel class of therapeutics called Helicon therapeutics. Its lead candidate, FOG-001, is a first-in-class inhibitor that blocks TCF-mediated β-catenin signaling, aimed at targeting common yet hard-to-treat drivers of cancer. The company uses integrated technologies to speed up discovery and scale development from research through potential commercialization. Compared with peers, Parabilis emphasizes a unique mechanism (TCF/β-catenin pathway inhibition) and a platform-driven approach designed to accelerate progression toward precision cancer therapies. The goal is to shape the future of precision medicine by delivering new treatments for previously untreatable diseases and advancing into clinical development with impactful candidates.

Company size
201-500
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2016

Recently Posted Jobs

Explore more opportunities at Parabilis Medicines

See more jobs